In this article, we are going to look at the 5 Best Performing Growth Stocks So Far in 2026. For a longer list and more details on how we picked these stocks, you can go to 10 Best Performing Growth Stocks So Far in 2026.
5. Dell Technologies Inc. (NYSE:DELL)
Year-Over-Year Revenue Growth: 38.57%
Year-to-Date Performance: 208.60%
Number of Hedge Fund Holders: 72
Dell Technologies Inc. (NYSE:DELL) ranks among the best-performing growth stocks so far in 2026. On June 1, Truist Securities increased its price target on Dell Technologies Inc. (NYSE:DELL) from $170 to $360 while keeping a Hold rating on the stock.
The research firm pointed to exceptionally strong demand and limited supply conditions. Truist believes that the second quarter of fiscal 2027 will likely show the same strength as seen in the first quarter.
The firm sees potential upside to Dell Technologies Inc.’s (NYSE:DELL) guidance for the second half of fiscal 2027 if it is able to secure sufficient supply to meet demand. Truist expects Dell Technologies Inc. (NYSE:DELL) to generate $174.3 billion in revenue for fiscal 2027, which is above the company’s own guidance range of $165 billion to $169 billion.
Looking ahead, Truist forecasts that the company’s sales will grow by 11% in fiscal 2028. The firm also expects earnings per share to reach $22, representing 10% year-over-year growth.
Dell Technologies Inc. (NYSE:DELL) is an American multinational technology company that designs, develops, manufactures, markets, sells, and supports integrated technology solutions, products, and services.
4. ImmunityBio, Inc. (NASDAQ:IBRX)
Year-Over-Year Revenue Growth: 351.53%
Year-to-Date Performance: 242.57%
Number of Hedge Fund Holders: 25
ImmunityBio, Inc. (NASDAQ:IBRX) ranks among the best-performing growth stocks so far in 2026. On June 1, ImmunityBio, Inc. (NASDAQ:IBRX) reported that it presented two research posters and one online publication at the American Society of Clinical Oncology (ASCO) Annual Meeting, which was held from May 29 to June 2, 2026, in Chicago.
The presentations included results from two randomized Phase 3 trials in advanced non-small cell lung cancer (NSCLC) and a matched adjusted indirect comparison (MAIC) in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). The presentations evaluated ANKTIVA (nogapendekin alfa inbakicept-pmln), the company’s IL-15 receptor agonist immunotherapy, which is designed to activate natural killer (NK) cells, CD4+ and CD8+ T cells, and memory T cells across different solid tumor types.
According to the report by ImmunityBio, Inc. (NASDAQ:IBRX), ANKTIVA is the first FDA-approved immunotherapy created to stimulate these important immune cells, which are depleted in patients with lymphopenia and play a key role in fighting cancer.
Growing long-term survival data across bladder, lung and other solid tumors support the idea that restoring immune competence and treating lymphopenia could become an important part of cancer care. The company believes these findings highlight the potential of activating and amplifying the immune system rather than suppressing it.
ImmunityBio, Inc. (NASDAQ:IBRX) is a biotechnology company that is focused on developing and commercializing next-generation immunotherapies for cancer and infectious diseases.
3. MaxLinear, Inc. (NASDAQ:MXL)
Year-Over-Year Revenue Growth: 40.89%
Year-to-Date Performance: 337.17%
Number of Hedge Fund Holders: 27
MaxLinear, Inc. (NASDAQ:MXL) ranks among the best-performing growth stocks so far in 2026. On June 3, Stifel increased its price target on MaxLinear, Inc. (NASDAQ:MXL) from $49 to $105 while keeping a Buy rating on the stock.
Analyst Tore Svanberg raised the price target after the company participated in Stifel’s 2026 Cross Sector 1-on-1 Conference. MaxLinear, Inc. (NASDAQ:MXL) was represented at the event by Co-Founder, Chairman, CEO and President Kishore Seendripu, along with CFO and Chief Corporate Strategy Officer Steven Litchfield.
The higher price target is based on a 65.0x CY27E price-to-earnings multiple and a 12.6x enterprise value-to-sales multiple. Stifel pointed to the structural rerating of data center and AI-exposed semiconductor companies as one of the reasons for the increase in the price target.
The firm also highlighted positive momentum across MaxLinear, Inc.’s (NASDAQ:MXL) product portfolio and said there could be upside to its current CY27E estimates.
MaxLinear, Inc. (NASDAQ:MXL) is a leading provider of radio frequency (RF), analog, digital and mixed-signal semiconductor products.
2. Applied Optoelectronics, Inc. (NASDAQ:AAOI)
Year-Over-Year Revenue Growth: 64.32%
Year-to-Date Performance: 346.97%
Number of Hedge Fund Holders: 55
Applied Optoelectronics, Inc. (NASDAQ:AAOI) ranks among the best-performing growth stocks so far in 2026. On May 8, Wolfe Research analyst George Notter reaffirmed its Peerperform rating on Applied Optoelectronics, Inc. (NASDAQ:AAOI).
The research firm pointed to concerns about the company’s ability to keep up with strong demand from cloud providers. Applied Optoelectronics, Inc. (NASDAQ:AAOI) reported Q1 sales of $151.1 million and a loss of $0.07 per share, falling short of market expectations of $157 million in revenue and a loss of $0.05 per share. This weaker performance was mainly due to lower-than-expected data center sales.
For Q2, Applied Optoelectronics, Inc. (NASDAQ:AAOI) expects revenue between $180 million and $198 million and earnings of $0.00 per share at the midpoint of its guidance. This compares to market estimates of $197 million in revenue and earnings of $0.07 per share.
The company lifted its 2026 outlook to $1.1 billion in sales and $140 million in operating profit, up from the previous guidance of $1 billion in sales and over $100 million in operating profit. Applied Optoelectronics, Inc. (NASDAQ:AAOI) also increased its forecast for monthly transceiver sales by mid-2027 to $471 million from its previous estimate of $378 million, supported by stronger revenue from 1.6T products.
Wolfe Research also introduced its 2028 forecast of $2.837 billion in sales and $5.00 in earnings per share for the company.
Applied Optoelectronics, Inc. (NASDAQ:AAOI) is a leading developer and manufacturer of advanced optical and Hybrid Fiber-Coax (HFC) networking products for AI datacenters, CATV and broadband fiber access networks. It serves customers across cloud computing, CATV broadband, telecommunications, and fiber-to-the-home (FTTH) markets.
1. SanDisk Corporation (NASDAQ:SNDK)
Year-Over-Year Revenue Growth: 82.76%
Year-to-Date Performance: 466.53%
Number of Hedge Fund Holders: 114
SanDisk Corporation (NASDAQ:SNDK) ranks among the best-performing growth stocks so far in 2026. On June 8, BofA analyst Wamsi Mohan lifted the firm’s price target on SanDisk Corporation (NASDAQ:SNDK) from $1,550 to $2,100 and kept a Buy rating on the stock after the company’s investor relations team attended the bank’s 2026 Global Technology Conference in San Francisco.
Investor discussion focused on SanDisk Corporation’s (NASDAQ:SNDK) multi-year supply agreements with customers. The company refers to these as new business models (NBMs). Under these contracts, prices remain fixed for an initial period before moving to variable pricing. The structure is designed to keep margins within the guidance even if prices hit the floor.
BofA sees these contracts as “win-win” because they secure supply for customers while also providing the company with more predictable financial results. BofA kept its Buy rating on SanDisk Corporation (NASDAQ:SNDK), pointing to “valuation, beneficial joint venture partnership, share gains, and long-term potential for industry consolidation.”
The bank also raised its fiscal 2027 revenue and EPS estimates for SanDisk Corporation (NASDAQ:SNDK) to $44 billion and $188, respectively, up from BofA’s previous forecasts of $37.7 billion and $154. The bank highlighted “strong trends in pricing and continued strong demand.”
Sandisk Corporation (NASDAQ:SNDK) is an American computer technology company that designs and manufactures flash solutions and advanced memory technologies, including SSDs, memory cards, and USB Flash Drives.
While we acknowledge the potential of SNDK to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than SNDK and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 12 Stocks Most Bought by Hedge Funds in Q1 2026 and 10 Best Single Digit Stocks to Buy Right Now.
Disclosure: None.
